本研究旨在检验乳腺癌（BC）患者原发和转移组织中癌干细胞（CSC）标志物ALDH1A1、CD133、CD44和MSI-1蛋白表达的临床意义。使用免疫组织化学方法评估55例接受1970年1月至2016年12月在神奈川肿瘤中心治疗的BC转移患者的原发和转移组织中ALDH1A1、CD133、CD44和MSI-1蛋白表达，并检查其与临床病理因素和生存率的关系。对于任何CSC标志物，原发和转移组织中的CSC标志物表达率没有显著差异。关于原发组织中CSC标志物表达和生存之间的关系，具有高CD133表达的患者具有显著较低的无复发生存和总体生存。经过多因素分析，CD133也是DFS的独立不良预测因子（危险比= 4.993，95％CI = 2.189-11.394，p = 0.0001）。相反，转移组织中CSC标志物的表达与生存之间没有显着关联。原发的BC组织中CD133的表达可能是BC患者复发的有用风险因素。版权所有 ©2023 International Institute of Anticancer Research（George J. Delinasios博士），保留所有权利。

This study aimed to examine the clinical significance of the protein expression of the cancer stem cell (CSC) markers ALDH1A1, CD133, CD44, and MSI-1 in primary and metastatic tissues of patients with breast cancer (BC).ALDH1A1, CD133, CD44, and MSI-1 protein expression in pairs of primary and metastatic tissues of 55 patients with BC with metastases treated at Kanagawa Cancer Center between January 1970 and December 2016 were evaluated using immunohistochemical assay and their association with clinicopathological factors and survival was examined.There were no significant differences in CSC marker expression rates between primary and metastatic tissues for any CSC markers. Regarding the relationship between CSC marker expression in primary tissues and survival, patients with high CD133 expression had significantly lower recurrence-free survival (DFS) and overall survival. On multivariate analysis, they were also a poor independent predictor of DFS (hazard ratio=4.993, 95%CI=2.189-11.394, p=0.0001). In contrast, there was no significant association between the expression of any CSC marker in metastatic tissues and survival.CD133 expression in the primary BC tissue may be a useful risk factor for recurrence in patients with BC.Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.